Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02145715
Other study ID # HM12/10174
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received March 1, 2013
Last updated June 25, 2015
Start date January 2013
Est. completion date January 2016

Study information

Verified date June 2015
Source University of Leeds
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Regulatory AgencyUnited Kingdom: Research Ethics Committee
Study type Interventional

Clinical Trial Summary

Velcade (bortezomib), thalidomide and dexamethasone (VTD) has been demonstrated to be a highly effective combination in both patients with previously untreated and those with relapsed multiple myeloma. In previously untreated patients VTD demonstrated clear superiority to TD as induction therapy prior to planned tandem autologous stem cell transplant.

The rationale of this trial is to combine a 'gold standard' antiMM combination with the HDAC inhibitor Panobinostat. There is emerging data to support the concept of clinical synergy between BTZ and HDACi's.

The purpose of this study is to determine the maximum tolerated dose (MTD) and estimated response rates of panobinostat, administered in combination with VTD, in subjects with relapsed and relapsed/refractory multiple myeloma.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 54
Est. completion date January 2016
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients with a previous diagnosis of multiple myeloma based on IMWG 2003 definitions:

- Monoclonal immunoglobulin (M component) on electrophoresis, and on immunofixation of serum or of total 24 hour urine

- Bone marrow (clonal) plasma cells = 10% or biopsy proven plasmacytoma

- Related organ or tissue impairment (CRAB symptoms, anemia, hypercalcemia, lytic bone lesions, renal insufficiency, hyperviscosity, amyloidosis or recurrent infections)

- Relapsed and relapsed-and-refractory myeloma who have received 1-4 prior lines and now require further treatment

- Able to give informed consent and willing to follow study protocol

- Aged 18 years or over

- ECOG Performance Status =2

- Required laboratory values within 14 days of registration:

- Absolute neutrophil count =1.0 x 109/L.

- Platelet count =100 x 109/L.

- Haemoglobin =8.0g/dL.

- Bilirubin =2 upper limit of normal (ULN)

- AST and/or ALT =2.5 ULN; except in subjects with known hepatic involvement, where AST and/or ALT =5.0 ULN

- Serum creatinine =2.0 ULN

- Corrected calcium =2.8 mmol/L.

- Anticipated survival of at least 3 months

- Evaluable disease per modified IWG criteria, utilising the following assessments as appropriate:

- Serum M protein = 10g/l.

- Urine M protein = 200mg/24 hours

- Serum free light chain assay: involved FLC level = 100mg/l. Provided serum FLC ratio is abnormal

- Female subjects of child-bearing potential must have a negative pregnancy test at baseline and agree to use dual methods of contraception for the duration of the study and must continue to do so for 3 months after the end of treatment. Male subjects must agree to use a barrier method of contraception for the duration of the study if sexually active with a female of child-bearing potential and must continue to do so for 3 months after the end of treatment.

Exclusion Criteria:

- Pregnant (positive pregnancy test) or breastfeeding women.

- Non-secretory Multiple Myeloma Previous anti-tumour therapies, including prior experimental agents or approved anti-tumour small molecules and biologics, within 28 days before the start of protocol treatment. Steroid therapy is permitted (maximum 160 mg dexamethasone or equivalent), but must be stopped 48 hours prior to study drug administration. Bisphosphonates for bone disease and radiotherapy for palliative intent are also permitted.

- Concurrent or previous malignancies (<12 months post end of treatment) at other sites with the exception of appropriately treated localised epithelial skin or cervical cancer, or incidental histologic findings of prostate cancer (TMN stage T1a or 1b). Patients with histories (=12 months) of other tumours may be entered.

- Poorly controlled or serious medical or psychiatric illness that, in the Investigator's opinion, is likely to interfere with participation and/or compliance in this clinical study

- Patients with significant cardiovascular disease (e.g. history of congestive heart failure requiring therapy, presence of severe valvular heart disease, presence of an atrial or ventricular arrhythmia requiring treatment, uncontrolled hypertension, a history of clinically significant QTc abnormalities)

- Active symptomatic fungal, bacterial, and/or viral infection including known active HIV or known viral (A, B, or C) hepatitis.

- Gastrointestinal disorders that may interfere with absorption of the study drug

- Patients who have been refractory to prior bortezomib, i.e. did not achieve at least an MR, or who have progressed on therapy or within 60 days of last dose

- Participants with peripheral neuropathy CTC grade 2 or higher or grade 1 with pain within 14 days prior to registration

- Any history or known hypersensitivity to any of the study medications or excipients

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Velcade

Thalidomide

Dexamethasone

Panobinostat


Locations

Country Name City State
United Kingdom Birmingham Heartlands Hospital Birmingham UK
United Kingdom Royal Liverpool University Hospital Liverpool
United Kingdom Guy's Hospital London
United Kingdom St Bartholomew's Hospital London
United Kingdom University College London Hospitals NHS Foundation Trust London

Sponsors (3)

Lead Sponsor Collaborator
Prof Jamie Cavenagh Myeloma UK, Novartis

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose limiting toxicities (DLTs) The number of participants experiencing DLTs within the first cycle of VTD-pano will be presented, with descriptive summaries of the specific DLTs observed. Summaries will be presented for each dose level. From cycle 1 day 1 up to the administration of cycle 2 day 1 (up to 22 days) Yes
Primary Proportion o f participants achieving at least partial response The proportion of participants achieving at least a partial response within 16 cycles of VTD-pano will be presented, with corresponding 80% and 95% confidence intervals within 16 cycles of therapy (an expected average of 48 weeks) No
Secondary Safety and toxicity The proportion of participants experiencing DLTs and other toxicities, overall and by cycle as graded by CTCAE V4.0. Throughout the trial, expected to be 3 years Yes
Secondary Proportion of patients with each maximum response category The number and proportion of participants in each response category within 16 cycles of VTD-pano will be presented with corresponding 95% confidence intervals. within 16 cycles of therapy (an expected average of 48 weeks) No
Secondary Time to maximum response to therapy Time to maximum response is defined as the time from registration until the patient achieves any of the categories CR, VGPR, PR, MR or SD as their maximum response. Median time to maximum response will be presented. from registration until the participant achieves any of the categories CR, VGPR, PR, MR or SD as their maximum response (up to 100 weeks - 48 weeks of treatment plus 52 weeks maintenance) No
Secondary Progression free survival A progression-free survival curve will be calculated using the Kaplan Meier method and median PFS estimates will be presented. from registration to first documented evidence of disease progression or death (up to 100 weeks) No
Secondary Compliance to therapy Compliance to therapy will be summarised descriptively, including number of doses missed and number of dose reductions throughout the treatment period. from initial treatment received as per protocol until treatment withdrawal (up to 100 weeks) No
Secondary Feasibility of panobinostat maintenance The duration of maintenance and reasons for stopping will be summarised up to 12 months No
Secondary Overall survival Overall survival (OS) curves will be calculated using the Kaplan Meier method. Median OS, and OS estimates at 12 months, will be presented, if appropriate. from registration to date of death No
Secondary The proportion of participants mobilising sufficient stem cells for transplant(out of those undergoing mobilisation) To be determined by the satisfactory collection of sufficient numbers of stem cells to support high-dose chemotherapy. up to 16 cycles of therapy (an expected average of 48 weeks) No
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1